Nav: Home

New Alzheimer's disease findings to be shared at international conference

December 05, 2016

WHAT: The conference will review the most important and promising developments in Alzheimer's disease research. It encourages the exchange of ideas and techniques used to tackle one of the 21st century's most intractable problems. The aim is to accelerate the development of effective Alzheimer's disease treatments.

USC scientists will be available for embargoed interviews prior to the conference when some 1,100 worldwide leaders in Alzheimer's disease research will congregate in San Diego for a three-day event at the 9th annual conference for Clinical Trials on Alzheimer's Disease (CTAD).

Paul Aisen, director of the USC Alzheimer's Therapeutic Research Institute (ATRI), founded CTAD in 2008 along with Jacques Touchon, Bruno Vellas and Mike Weiner. Attendance at the conference will nearly triple this year compared to its inaugural year.

More than 70 researchers at USC are devoted to reimagining the way Alzheimer's disease is studied, diagnosed, prevented, treated and -- perhaps one day -- cured. These are the topics six USC scientists will speak about at CTAD:
  • Phase 3 clinical trial that used Eli Lilly's drug solanezumab in people with mild dementia
  • The search for Alzheimer's disease biomarkers in people with Down syndrome: a genetically predisposed population
  • Stem cell use and regenerative therapeutics for Alzheimer's disease treatment
  • Phase 3 clinical trial that used the drug LMTM on people with mild Alzheimer's disease to inhibit the accumulation of tau proteins
  • Safety and efficacy of low-dose Ladostigil in patients with mild cognitive impairment
  • The APOE gene and low levels of amyloid beta protein 42 (Abeta42) in cerebrospinal fluid may influence the activity of omega-3 fatty acids, which enhance synaptic plasticity, learning and memory
  • Continued progress on Alzheimer's disease trial design
  • Using algorithms to automatically classify adverse effects in clinical studies of Alzheimer's disease
  • Using an interactive, open-source platform to monitor risk in Alzheimer's disease clinical trials


WHEN: Thursday, Dec. 8 -- Saturday, Dec. 10

The presentation "EXPEDITION3: A phase 3 trial of solanezumab in mild dementia due to Alzheimer's disease" will take place from 6:15-7:45 p.m. PST on Thursday, Dec. 8 and will be streamed live at http://www.ctad-alzheimer.com/live-expedition-3-webcast.

WHERE: Marriott Marquis San Diego Marina
333 West Harbor Drive
San Diego, CA 92101

WHO:
  • Paul Aisen, director of the USC Alzheimer's Therapeutic Research Institute
  • Michael Rafii, clinical director of the USC Alzheimer's Therapeutic Research Institute
  • Lon Schneider, director of the USC California Alzheimer's Disease Center
  • Hussein Yassine, assistant professor of medicine at the Keck School of Medicine of USC
  • Gustavo Jimenez-Maggiora, director of informatics at the USC Alzheimer's Therapeutic Research Institute
  • Rema Raman, director of biostatistics at the USC Alzheimer's Therapeutic Research Institute


RSVP for PRESS PASS: Call (213) 300-1381 or email zvuong@usc.edu
-end-


University of Southern California

Related Clinical Trials Articles:

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.
Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.
Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.
Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.
Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.
Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.
Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.
When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.
New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.
Telemedicine helps improve participation in clinical trials
Videos and creative uses of other visuals provide a novel way to obtain informed consent during clinical trials to improve participants' understanding and retention of trial information, according to a study by Nemours Children's Health System presented at the American Thoracic Society (ATS) Annual Conference.
More Clinical Trials News and Clinical Trials Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.